|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1750 - 0.2040|
|52 Week Range||0.1400 - 0.8200|
|Beta (3Y Monthly)||-0.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.
On November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products. LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the success of its first annual, "Innovation in Medical Cannabis Therapies" (IMCT) Symposium, held on Friday, November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.
LAS VEGAS, Dec. 12, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their first crop in the rapidly expanding hemp market expects to yield a gross profit of $0.7million dollars as well as seeds and genetics. These seeds and genetic information will provide the mother plants in order to expand the program, which should prove to be a significant revenue generator for the Company. An integral part of the Company's success is its partnership with The Colorado Hemp Project (CHP). "GB Sciences told us what they wanted out of the plants, and we worked together to fill in the blanks," remarked Wild Bill.
Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia". LAS ...
LAS VEGAS, Dec. 7, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC. The Master Research and Development Agreement comes from the parties' desire to participate in joint research and development projects arising out of the production of therapeutic cannabis in Louisiana. As a public institution of higher education, the LSU AgCenter's public-private partnership with GB Sciences Louisiana represents a first in the therapeutic cannabis industry.
Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, Nov. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai Biotechnology, LLC, Dr. Alexander Stokes, and researchers from the University of Kyoto, Japan.
LAS VEGAS, Nov. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain. "We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain," said Dr. Andrea Small-Howard.
Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN. In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.
LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma. This company has been awarded cultivation, processing and dispensary licenses by the Oklahoma Medical Marijuana Authority. Under their agreement, GB Sciences will design a cultivation and processing facility in Oklahoma, and provide 4EVERGRN with best-practice operating procedures. 4EVERGRN will produce and distribute GB Sciences products and brands under a licensing agreement in exchange for a royalty to GB Sciences. The agreement can be terminated if quality standards are abridged or compromised.
Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 6, 2018 /PR Newswire/-- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN. In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.
On November 9th, an international medical cannabis symposium, led by Dr. Andrea Small-Howard, will be held in Las Vegas, NV. LAS VEGAS, Nov. 1, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces sponsorship of a one day, November 9th, international medical cannabis symposium, "Innovation in Medical Cannabis Therapies", under the direction of Dr. Andrea Small-Howard, Chief Science Officer and a member of the Board of Directors for GB Sciences.
Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Oct. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) introduces "the brain nurse", Meredith Patterson RN, BSN, CRRN. In her over 25yrs of experience in neuroscience nursing, Meredith has learned the value of questions. When she first heard patients extolling the virtues of cannabis for serious medical conditions, such as Parkinson's as well as difficult to treat ongoing conditions such as chronic pain, she got curious.
Harvesting the first crop, in association with the Colorado Hemp Project, GB Sciences explores hemp as a highly reliable source of hard to find cannabinoids and terpenes for cannabis-based medical formulations as well as a fresh source of revenue from the sale of hemp oil and related products. LAS VEGAS, Oct. 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the harvesting of its first hemp crop in association with the Colorado Hemp Project. Following closely on the overall philosophy and strategy of the Company, hemp is planned to provide both a reliable source of hard to find cannabinoids and terpenes necessary to manufacture cannabis-based medical formulations and also provide a fresh revenue source through the sale of bulk hemp oil and other hemp related products.
Mr. Poss will speak on GB Sciences' collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids. LAS VEGAS , Oct. 10, 2018 ...
LAS VEGAS, Oct. 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th. According to the conference organizers, "CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world's top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis.
GB Sciences explores the therapeutic potential of the chemical diversity within different varieties of the cannabis plant to make better medicine for patients worldwide. LAS VEGAS, Oct. 3, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece. Titled: The Cannabis Metabolomics ("Canna-bolomics") Project, the program will analyze each of GB Sciences' cultivars to determine whether additional molecules in these cultivars, and hundreds of other natural cannabis and hemp cultivars, show significant promise to treat diseases. "GB Sciences is widening the lens with which we observe and characterize plant-based, cannabis-derived chemical mixtures for human therapies starting from GB Sciences' stock genotypes.
LAS VEGAS, Oct. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)'s decision to reschedule GW Pharmaceuticals' Epidiolex, from Schedule I to Schedule V of the Controlled Substances Act (CSA). In June of 2018, Epidiolex was the first ever plant-based, cannabis drug to be approved by the Food and Drug Administration (FDA). There is now both a regulatory precedent for market approval on a plant-based cannabinoid-containing drug and a path to its commercialization.
GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease SWINDON, U.K. , and LAS VEGAS , Sept. 26, ...
The new license provides access to the largest growing sectors in the cannabis industry. Multiple new brands for both medical and recreational markets being prepped for retail sales. LAS VEGAS, Sept. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has been granted a recreational production license for the manufacture of cannabis oils. Oils are the base ingredient for vape products, tinctures, edibles, and nutraceutical formulations.
LAS VEGAS, Sept. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has mobilized cannabis industry thought leaders to discuss both the immense potential for cannabis-based therapies and the challenges of delivering on their medical promise under state regulated programs at their fourth annual "Innovation in Medical Cannabis Therapies" symposium on November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, NV. This event has attracted innovative leaders in cannabis biotech, nanotech, metabolomics, cultivation and extraction tech. GB Sciences is pleased to announce this will include representatives from US and international research universities, cannabis industry leaders, clinical research organizations, and cannabis tech companies.
Dr. Andrea Small-Howard is featured in the "Meeting of the Minds" at the two-day educational conference hosted on the historic Queen Mary. LAS VEGAS, Sept. 18, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research Initiatives. Of great interest to this panel is The Medical Cannabis Research Act of 2018, which was unanimously approved by the House Judiciary Committee with widespread bipartisan support on September 13th.
In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program. BATON ROUGE, La. , Aug. 23, 2018 /PRNewswire/ -- GB Sciences, ...
The first plants generated through tissue culture have now moved into their environmentally controlled cannabis grow pod. BATON ROUGE, La., Aug. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the LSU Agricultural Center (LSU AgCenter), have now commenced operation in the environmentally controlled grow pod. Representatives from nine Louisiana pharmacies authorized to dispense medical cannabis toured our high-tech 36,000-sq ft GB Sciences facility in Baton Rouge, LA.
This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial. LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.